Page 2 - Patrick Roth News Today

LAUSANNE, Switzerland, May 17, 2023 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a privately-owned,...

Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA damage repair (DDR) and reverse the poor prognosis for patients with GBM. This multicenter clinical trial launched in the US, Spain and Switzerland is following the preclinical GBM data presented at the annual Amer...

Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%.Debiopharm is combining its potent, brain penetrant

WENY News is the ABC, CBS & CW affiliate serving the Twin Tiers region of New York and Pennsylvania.

WENY News is the ABC, CBS & CW affiliate serving the Twin Tiers region of New York and Pennsylvania.

A consortium of industry and research partners including French Biotech Covalab, focused on  recombinant proteins and antibodies for diagnostics and therapeutics; CimCure (Netherlands), Amsterdam UMC (The Netherlands) and the University of Zurich (Switzerland, have received a €1. Click to read more...

CimCure, Covalab, Amsterdam UMC and the University of Zurich (Switzerland), have received a €1.06M grant from EUREKA Eurostars. 

CimCure, Covalab, Amsterdam UMC and the University of Zurich (Switzerland), have received a €1.06M grant from EUREKA Eurostars. 

Risk Strategies named Patrick Roth senior vice president, growth leader for the Central and West regions. Roth is located in Colorado. He will be

He brings 17 years' experience in recruiting and improving producers to the firm